var data={"title":"Levalbuterol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levalbuterol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6445?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">see &quot;Levalbuterol: Drug information&quot;</a> and <a href=\"topic.htm?path=levalbuterol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levalbuterol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187525\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xopenex;</li>\n      <li>Xopenex Concentrate;</li>\n      <li>Xopenex HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059708\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Beta<sub>2</sub>-Adrenergic Agonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sympathomimetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443761\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May consider using half of the albuterol dose; albuterol is a 1:1 racemic mixture and levalbuterol is the active isomer; limited data available. <b>Dosage expressed in terms of mg levalbuterol.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchodilation:</b> Nebulization: 0.31 mg/dose every 8 hours was administered to 31 VLBW neonates (mean GA: 28.1 weeks; mean birth weight: 1,127 g) for &gt;2 weeks; no untoward hemodynamic effects were noted (Mhanna 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059701\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">see &quot;Levalbuterol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Dosage expressed in terms of mg levalbuterol.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, acute exacerbation</b> (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nebulization:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 0.075 mg/kg/dose (minimum dose: 1.25 mg/dose) every 20 minutes for 3 doses, then 0.075 to 0.15 mg/kg/dose (maximum dose: 5 mg/dose) every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 1.25 to 2.5 mg every 20 minutes for 3 doses, then 1.25 to 5 mg every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Inhalation, aerosol (metered dose inhaler</i>)<i>:</i> 45 mcg/spray:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 4 to 8 puffs every 20 minutes for 3 doses, then every 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 4 to 8 puffs every 20 minutes for up to 4 hours, then every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, maintenance therapy (nonacute)</b> (NAEPP 2007): <b>Note</b>: Not recommended for long-term, daily maintenance treatment; regular use exceeding 2 days/week for symptom control indicates the need for additional long-term control therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nebulization:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;4 years: 0.31 to 1.25 mg every 4 to 6 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to &lt;12 years: 0.31 to 0.63 mg every 8 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 0.63 to 1.25 mg every 8 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Inhalation, aerosol (metered dose inhaler):</i> 45 mcg/spray: Children &ge;4 years and Adolescents: 2 inhalations every 4 to 6 hours as needed; per the manufacturer, 1 inhalation every 4 hours may be sufficient in some patients; maximum dose: 2 inhalations every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchospasm:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metered-dose inhaler:</i> 45 mcg/spray: 2 inhalations every 4 to 6 hours as needed; in some patients, 1 inhalation every 4 hours may be sufficient (maximum: 2 inhalations every 4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Solution for nebulization:</i> Initial: 0.63 mg 3 times daily at intervals of 6 to 8 hours; dosage may be increased to 1.25 mg 3 times daily with close monitoring for adverse effects (maximum: 1.25 mg 3 times daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Exacerbation of asthma (acute, severe) </b>(NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metered-dose inhaler:</i> 45 mcg/spray: 4 to 8 inhalations every 20 minutes for up to 4 hours, then every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Solution for nebulization: </i>1.25 to 2.5 mg every 20 minutes for 3 doses, then 1.25 to 5 mg every 1 to 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187503\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol, Inhalation, as tartrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xopenex HFA: 45 mcg/actuation (15 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 45 mcg/actuation (15 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xopenex: 0.63 mg/3 mL (3 mL [DSC]); 1.25 mg/3 mL (3 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.31 mg/3 mL (3 mL); 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 1.25 mg/0.5 mL (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nebulization Solution, Inhalation, as hydrochloride [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xopenex: 0.31 mg/3 mL (3 mL); 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xopenex Concentrate: 1.25 mg/0.5 mL (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.31 mg/3 mL (3 mL); 0.63 mg/3 mL (3 mL); 1.25 mg/3 mL (3 mL); 1.25 mg/0.5 mL (1 ea, 30 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187488\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21001744\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">see &quot;Levalbuterol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\"> Xopenex HFA 15 g canisters contain 200 inhalations. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059711\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral Inhalation: In children &lt;4 years, a face mask with either the metered dose inhaler or nebulizer is recommended (GINA 2016; NAEPP 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: Dilution required for concentrated solution. Safety and efficacy were established when administered with the following nebulizers: PARI LC Jet, PARI LC Plus, as well as the following compressors: PARI Master, Dura-Neb 2000, and Dura-Neb 3000. Blow-by administration is not recommended, use a mask device if patient unable to hold mouthpiece in mouth for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation, aerosol (metered dose inhaler): Shake well before use. Prime the inhaler (before first use or if it has not been used for more than 3 days) by releasing 4 test sprays into the air away from the face. Clean actuator (mouthpiece) weekly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187521\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metered-dose inhaler: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from freezing and direct sunlight. Store with mouthpiece down. Discard when the dose indicator display shows zero, corresponding to 200 actuations. Do not store near heat or open flame or expose to temperatures &gt;120&deg;F. Do not puncture or incinerate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization solution: Store in protective foil pouch at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light and excessive heat. Vials should be used within 2 weeks after opening protective pouch. Use within 1 week and protect from light if removed from pouch. Vials of concentrated solution should be used immediately after removing from protective pouch.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059710\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment and prevention of bronchospasm in patients with reversible obstructive airway disease (Inhalation aerosol: FDA approved in ages &ge;4 years and adults; Nebulization solution: FDA approved in ages &ge;6 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187551\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Xopenex may be confused with Xanax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187549\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Tachycardia (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety (adolescents and adults), dizziness (adolescents and adults), headache (children), migraine (adolescents and adults), nervousness (adolescents and adults), pain (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (children), urticaria (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum potassium, increased heart rate, increased serum glucose, paradoxical bronchospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (children, adolescents, and adults), dyspepsia (adolescents and adults), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (including bronchospasm, oropharyngeal edema)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Leg cramps (adolescents and adults), myalgia, tremor (adolescents and adults), weakness (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchitis (children), cough (adolescents and adults), flu-like symptoms (adolescents and adults), nasal mucosa swelling, pharyngitis, rhinitis, sinusitis (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury (children, adolescents, and adults), fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acne vulgaris, anaphylaxis, angina pectoris, angioedema, atrial fibrillation, cardiac arrhythmia, chest pain, dry throat, dysmenorrhea, dyspnea, ECG abnormality, epistaxis, extrasystoles, gastroenteritis, gastroesophageal reflux disease, hematuria, hyperesthesia (hand), hypertension, hypokalemia, metabolic acidosis, nausea, otalgia, paresthesia, pulmonary disease, supraventricular cardiac arrhythmia, syncope, vulvovaginal candidiasis, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187509\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to levalbuterol, albuterol, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187492\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Rarely, life-threatening paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response. Discontinue immediately and treat with an alternative therapy. Paradoxical bronchospasm is frequently associated with first use of a new canister or vial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, anaphylaxis, oropharyngeal edema) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, or hypertension); beta agonists may cause elevation in blood pressure and heart rate and result in CNS stimulation/excitation. Beta-2 agonists may also increase risk of arrhythmias and electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub>-agonists may increase serum glucose and aggravate ketoacidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; beta<sub>2</sub>-agonists may decrease serum potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; drug clearance is decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Optimize anti-inflammatory treatment before initiating maintenance treatment with levalbuterol. Do not use as a component of long-term therapy without an anti-inflammatory agent. Only the mildest form of asthma (step 1 and/or exercise-induced) would not require concurrent use based on asthma guidelines (NAEPP 2007). If patients need more doses than usual, this may be a sign of asthma destabilization; patient should be reevaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed. A spacer device or valved holding chamber is recommended when using a metered-dose inhaler.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299585\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187497\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12546&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187499\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187512\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Congenital anomalies (cleft palate, limb defects) have rarely been reported following maternal use of racemic albuterol during pregnancy. Multiple medications were used in most cases, no specific pattern of defects has been reported, and no relationship to racemic albuterol has been established. Beta-agonists may interfere with uterine contractility if administered during labor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased risk of perinatal mortality, pre-eclampsia, preterm birth, and low birth weight infants. Acute asthma exacerbations should be treated aggressively with short-acting beta-2 agonists (SABA) to prevent fetal hypoxia (GINA 2016; Namazy 2016). If high doses of SABA are needed during the last 48 hours of labor and delivery, monitor blood glucose in the newborn for 24 hours after birth (GINA 2016). If initiating treatment during pregnancy, use of an agent with more data in pregnant women may be preferred (Namazy 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059707\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor asthma symptoms, FEV<sub>1</sub>, peak flow and/or other pulmonary function tests, blood pressure, heart rate, CNS stimulation; arterial or capillary blood gases (if patient's condition warrants); serum potassium, serum glucose (in selected patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187491\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Relaxes bronchial smooth muscle by action on beta<sub>2</sub>-receptors with little effect on heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187508\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (as measured by a 15% increase in FEV<sub>1</sub>):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metered-dose inhaler: 5.5 to 10.2 minutes; Peak effect: 76 to 78 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization solution: 10 to 17 minutes; Peak effect: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (as measured by a 15% increase in FEV<sub>1</sub>):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metered-dose inhaler: 3 to 4 hours (up to 6 hours in some patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization solution: 5 to 6 hours (up to 8 hours in some patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: A portion of inhaled dose is absorbed to systemic circulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Metabolized primarily in the gastrointestinal tract via SULT1A3 (sulfotransferase)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3.3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Nebulization solution: Children: 0.3 to 0.6 hours, Adults: 0.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 100%), feces (&lt;20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059716\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Levalbuterol administered in <sup>1</sup>/<sub>2</sub> the mg dose of albuterol (eg, 0.63 mg levalbuterol to 1.25 mg albuterol) provides comparable efficacy and safety (NAEPP 2007). One inhalation of levalbuterol HFA delivers 59 mcg of levalbuterol tartrate, equivalent to 45 mcg of levalbuterol free base.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187511\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Levalbuterol Tartrate Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mcg/ACT (15 g): $73.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Xopenex HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mcg/ACT (15 g): $81.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Levalbuterol HCl Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.31 mg/3 mL (3 mL): $6.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.63 mg/3 mL (3 mL): $6.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/0.5 mL (1): $6.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/3 mL (3 mL): $6.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Xopenex Concentrate Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/0.5 mL (1): $8.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Nebulization</b> (Xopenex Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.31 mg/3 mL (3 mL): $11.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.63 mg/3 mL (3 mL): $11.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/3 mL (3 mL): $11.87</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707686\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Seramar (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org. Updated 2016. Accessed November 18, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lotvall J, Palmqvist M, Arvidsson P, et al, &ldquo;The Therapeutic Ratio of R-Albuterol Is Comparable With That of RS-Albuterol in Asthmatic Patients,&rdquo; <i>J Allergy Clin Immunol</i>, 2001, 108(5):726-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levalbuterol-pediatric-drug-information/abstract-text/11692096/pubmed\" target=\"_blank\" id=\"11692096\">11692096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mhanna MJ, Patel JS, Patel S, et al, &quot;The Effects of Racemic Albuterol Versus Levalbuterol in Very Low Birth Weight Infants,&quot; <i>Pediatr Pulmonol</i>, 2009, 44(8):778-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levalbuterol-pediatric-drug-information/abstract-text/19598281/pubmed\" target=\"_blank\" id=\"19598281\">19598281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milgrom H, Skoner DP, Bensch G, et al, &ldquo;Low-Dose Levalbuterol in Children With Asthma: Safety and Efficacy in Comparison With Placebo and Racemic Albuterol,&rdquo; <i>J Allergy Clin Immunol</i>, 2001, 108(6):938-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levalbuterol-pediatric-drug-information/abstract-text/11742271/pubmed\" target=\"_blank\" id=\"11742271\">11742271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xopenex (levalbuterol) [prescribing information]. Lake Forest, IL: Akorn; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xopenex HFA (levalbuterol) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xopenex inhalation solution concentrate (levalbuterol) [prescribing information]. Lake Forest, IL: Akorn; January 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12546 Version 152.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187525\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059708\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443761\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059701\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187503\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187488\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21001744\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059711\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187521\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059710\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187551\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187549\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187509\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187492\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299585\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187497\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187499\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187512\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059707\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187491\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187508\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1059716\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187511\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707686\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12546|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levalbuterol-drug-information\" class=\"drug drug_general\">Levalbuterol: Drug information</a></li><li><a href=\"topic.htm?path=levalbuterol-patient-drug-information\" class=\"drug drug_patient\">Levalbuterol: Patient drug information</a></li></ul></div></div>","javascript":null}